Weight loss as new diabetes target could boost sales of Novo Nordisk's obesity drug

Lasting weight loss should be the primary treatment target for people with type 2 diabetes, according to several researchers. Novo Nordisk, which has recently launched Wegovy, a drug that can lead to weight loss of up to 17 percent on average, agrees with the assessment.
Photo: Jens Dresling/Ritzau Scanpix
Photo: Jens Dresling/Ritzau Scanpix
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY DANIEL PEDERSEN

Wallets at Novo Nordisk might get fatter if enduring weight loss becomes the primary treatment goal for people with type 2 diabetes, as several researchers have proposed in the Lancet, Danish business daily Børsen reports on Wednesday.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading